Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study
Henry Krum(Australian Regenerative Medicine Institute), Murray Esler(Baker Heart and Diabetes Institute), Markus P. Schlaich(The University of Western Australia), S. Thambar(John Hunter Hospital), William T. Abraham(The Ohio State University), R. Whitbourn(St Vincent's Hospital), Krzysztof Bartuś(Jagiellonian University), Paul A. Sobotka(The Ohio State University), Jerzy Sadowski(Jagiellonian University), Horst Sievert(Cardiovascular Center Frankfurt), A. Walton(The Alfred Hospital), Bogusław Kapelak(Jagiellonian University)
Cited by 2,104
Related Papers
Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial
|The Lancet|2010|2.2k
Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE)
|American Heart Journal|2005|2.1k
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
|The Lancet|2017|1.3k
Targeted Anticytokine Therapy in Patients With Chronic Heart Failure
|Circulation|2004|1.2k
Aliskiren, ALTITUDE, and the Implications for ATMOSPHERE
|European Journal of Heart Failure|2012|1.1k